Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Linh Nguyen, M.D.

Co-Author

This page shows the publications co-authored by Paul Nguyen and Peter Orio.
Connection Strength

7.646
  1. Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. Brachytherapy. 2021 Jan-Feb; 20(1):1-9.
    View in: PubMed
    Score: 0.232
  2. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 09; 38(9):735.e9-735.e15.
    View in: PubMed
    Score: 0.227
  3. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948.
    View in: PubMed
    Score: 0.213
  4. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203.
    View in: PubMed
    Score: 0.205
  5. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191.
    View in: PubMed
    Score: 0.205
  6. Reply to Partial gland therapy for prostate cancer. Cancer. 2019 03 01; 125(5):819-820.
    View in: PubMed
    Score: 0.204
  7. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41.
    View in: PubMed
    Score: 0.202
  8. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959.
    View in: PubMed
    Score: 0.201
  9. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer. 2018 09 01; 124(17):3528-3535.
    View in: PubMed
    Score: 0.198
  10. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154.
    View in: PubMed
    Score: 0.193
  11. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20.
    View in: PubMed
    Score: 0.190
  12. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149.
    View in: PubMed
    Score: 0.190
  13. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234.
    View in: PubMed
    Score: 0.189
  14. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58.
    View in: PubMed
    Score: 0.187
  15. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840.
    View in: PubMed
    Score: 0.186
  16. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76.
    View in: PubMed
    Score: 0.184
  17. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32.
    View in: PubMed
    Score: 0.183
  18. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343.
    View in: PubMed
    Score: 0.180
  19. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192.
    View in: PubMed
    Score: 0.179
  20. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
    View in: PubMed
    Score: 0.176
  21. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
    View in: PubMed
    Score: 0.173
  22. Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):624-8.
    View in: PubMed
    Score: 0.173
  23. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016 Nov - Dec; 15(6):701-706.
    View in: PubMed
    Score: 0.171
  24. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12.
    View in: PubMed
    Score: 0.168
  25. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6.
    View in: PubMed
    Score: 0.168
  26. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90.
    View in: PubMed
    Score: 0.166
  27. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
    View in: PubMed
    Score: 0.163
  28. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
    View in: PubMed
    Score: 0.159
  29. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6.
    View in: PubMed
    Score: 0.158
  30. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
    View in: PubMed
    Score: 0.156
  31. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
    View in: PubMed
    Score: 0.156
  32. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406.
    View in: PubMed
    Score: 0.154
  33. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282.
    View in: PubMed
    Score: 0.153
  34. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014 Sep 09; 9:200.
    View in: PubMed
    Score: 0.152
  35. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9.
    View in: PubMed
    Score: 0.149
  36. Placement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planning. Brachytherapy. 2014 Jul-Aug; 13(4):375-9.
    View in: PubMed
    Score: 0.146
  37. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014 Mar-Apr; 13(2):152-6.
    View in: PubMed
    Score: 0.140
  38. Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232.
    View in: PubMed
    Score: 0.136
  39. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy. 2013 Jan-Feb; 12(1):77-83.
    View in: PubMed
    Score: 0.129
  40. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73.
    View in: PubMed
    Score: 0.128
  41. Variability in prostate volume as determined by MRI versus ultrasound and its impact on treatment recommendations for patients with favorable-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):249.
    View in: PubMed
    Score: 0.127
  42. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178.
    View in: PubMed
    Score: 0.124
  43. Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys. 2021 Aug 16.
    View in: PubMed
    Score: 0.061
  44. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiother Oncol. 2021 08; 161:241-250.
    View in: PubMed
    Score: 0.061
  45. Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology. 2020 Nov; 145:197-203.
    View in: PubMed
    Score: 0.057
  46. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978.
    View in: PubMed
    Score: 0.054
  47. Determining optimal eluter design by modeling physical dose enhancement in brachytherapy. Med Phys. 2018 Jun 15.
    View in: PubMed
    Score: 0.049
  48. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911.
    View in: PubMed
    Score: 0.046
  49. A novel approach to an automated needle insertion in brachytherapy procedures. Med Biol Eng Comput. 2018 Feb; 56(2):273-287.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.